Filtered By:
Condition: Stroke
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 1527 results found since Jan 2013.

Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice
Biomed Pharmacother. 2023 Jun 21;165:115020. doi: 10.1016/j.biopha.2023.115020. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and in recent years the pharmacological approach has been strongly implemented; in Italy, the prescription of the non-vitamin K oral anticoagulants (NOAC) was also extended to General Practitioners (GPs) since 2020. The aim of the present study was to investigate the GPs prescribing behaviour of NOACs. An observational study was performed by using the computerized medical record of 14 GPs in Sicily: patients affected by AF were selected and st...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 23, 2023 Category: Drugs & Pharmacology Authors: M Rottura S F A Drago A Molonia N Irrera S Marino R Scoglio L Orlando M Gigliotti De Fazio F Squadrito V Arcoraci E Imbalzano on the behalf of Audit & Research Messina Primary Care Group Source Type: research

Molecules, Vol. 28, Pages 4953: Electrochemical Disposable Biosensor to Monitor Dabigatran in Point-of-Care Anticoagulation Therapy
riero Dabigatran etexilate, an oral prodrug, is often used to treat complications linked to thrombosis. Dabigatran (DAB, active form) does not need to be monitored. However, there are several conditions, such as reduced renal function, traumatic bleeding, emergency surgery, the need for thrombolytic therapy in acute stroke, or the requirement to use other forms of anticoagulation, where knowing the concentration of DAB in the blood is indispensable. Unfortunately, there are no convenient DAB-specific point-of-care tests available. To solve this problem, two disposable sensors were constructed and optimised in this work...
Source: Molecules - June 23, 2023 Category: Chemistry Authors: Ashwin K. V. Mruthunjaya Ronald C. Chatelier Angel A. J. Torriero Tags: Article Source Type: research

Direct oral anticoagulants: patient reported adherence and minor bleedings
AbstractData regarding adherence and minor bleeding on direct oral anticoagulants in everyday life are still sparse. Inclusion criteria: treatment initiated with dabigatran, rivaroxaban or apixaban in non-valvular atrial fibrillation patients from a center in northern Sweden between 2011 and 2019 (n  = 668). Exclusion criteria: cognitive impairment, dose dispensing, need of interpreter or hospital admission (n = 67). By a telephone interview adherence was measured in 569 patients (response rate 94.8%) using the 8-item Morisky medication adherence scale and minor bleeding was asked for. CHA2DS2-VASc and HAS-BLED sco...
Source: Journal of Thrombosis and Thrombolysis - June 22, 2023 Category: Hematology Source Type: research

Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis
ConclusionsBased on current evidence, for stroke prevention in patients with AF, the safest DOAC is apixaban in terms of non-major bleeding. This suggests that apixaban may have a lower risk of non-major bleeding than other anticoagulants and may help provide some clinical reference for choosing a more appropriate drug for the patient.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States
ConclusionsMore than one-quarter of patients experienced PMN within 30 days of their initial prescription order. This rate decreased over a longer period, suggesting a delay in fills. Understanding the factors associated with PMN is warranted to develop effective interventions for improving OAC treatment rates in NVAF.
Source: American Journal of Cardiovascular Drugs - June 10, 2023 Category: Cardiology Source Type: research

Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials
AbstractBalancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for treating patients with AF in international guidelines. Our objective was to assess the safety of long-term intake of DOACs in older adults with AF. We included RCTs in elderly ( ≥ 65 years) patients with AF. A systematic search in MEDLINE and EMBASE was performed on 19 April 2022. For determination of risk of bias, the RoB 2 tool was applied. We pooled outcomes using random-effects meta-analyses. The quality of evidence was as...
Source: AGE - June 1, 2023 Category: Geriatrics Source Type: research

Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry
CONCLUSIONS: Among patients hospitalized with COVID-19, patients with AF were older, had more comorbidities and had a higher risk of major bleeding. Age and elevated transaminases during hospitalization, but not AF nor anticoagulant treatment increased the risk of all-cause death.PMID:37189306 | DOI:10.1080/03007995.2023.2204009
Source: Current Medical Research and Opinion - May 16, 2023 Category: Research Authors: Juan Jos é Cerezo Manchado Teodoro Iturbe Hern ández Mar ía Del Carmen Martínez Pacheco Ignacio Gil Ortega Desir ée Campoy Tania Canals Pernas Laia Mart ínez Serra Katia Jessica Flores Aparco C ésar Andrés Velásquez Escandón Antonio Mart ínez F Source Type: research

DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes
This article is protected by copyright. All rights reserved.PMID:37178305 | DOI:10.1002/jcph.2283
Source: The Journal of Clinical Pharmacology - May 13, 2023 Category: Drugs & Pharmacology Authors: Nauka J Bhalodia Jesse Cheng Connor R Deri Kelsey Stahl Heather Heiney Olivia Marchionda Carlo J Iasella James C Coons Source Type: research